| 证券代码：000411 | 证券简称：英特集团 | 公告编号：2025-047 | | --- | --- | --- | | 债券代码：127028 | 债券简称：英特转债 | | 浙江英特集团股份有限公司 十届十次监事会议决议公告 特此公告。 浙江英特集团股份有限公司监事会 2025 年 11 月 6 日 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 1 2025 年 10 月 31 日，浙江英特集团股份有限公司以电子邮件、专人送达方式向全体监 事发出了召开十届十次监事会议的通知。会议于 2025 年 11 月 5 日以通讯表决方式召开。会 议应到监事 5 人，出席会议的监事 5 人，缺席会议的监事 0 人。本次会议的召开符合有关法 律、行政法规、部门规章、规范性文件和公司章程的规定。会议采用记名表决方式对通知中 所列事项进行了表决，形成以下决议： 一、审议通过了《关于变更公司住所、营业期限及修订<公司章程>等制度的议案》（同 意 5 票、反对 0 票、弃权 0 票）。 相关内容披露在同日的巨潮资讯网（http://www.cninfo.com.cn ...

| | | 浙江英特集团股份有限公司 十届十七次董事会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 2025 年 10 月 31 日，浙江英特集团股份有限公司以电子邮件、专人送达方式向全体董 事发出了召开十届十七次董事会议的通知，会议于 2025 年 11 月 5 日以通讯表决方式召开。 会议应到董事 11 人，实际出席会议的董事 11 人，缺席会议的董事 0 人。本次会议的召开 符合有关法律、行政法规、部门规章、规范性文件和公司章程的规定。会议采用记名表决 方式对通知中所列事项进行了表决，形成以下决议： 一、审议通过了《关于变更公司住所、营业期限及修订〈公司章程〉等制度的议案》 （11 票同意，0 票反对，0 票弃权）。 相关内容披露在同日的巨潮资讯网（http://www.cninfo.com.cn）和证券时报上。 本议案尚需提交公司股东大会审议。 二、审议通过了《关于制定〈董事、高级管理人员离职管理制度〉〈市值管理制度〉 的议案》（11 票同意，0 票反对，0 票弃权）。 《 董 事 、 高 级 管 理 人 员 离 职 管 理 制 度 》 ...

Group 1: Company Overview - The main business of the company includes wholesale and retail of pharmaceuticals, traditional Chinese medicine, biological products, and medical devices [2] - The operational model involves purchasing products from upstream pharmaceutical manufacturers and supplying them to downstream medical institutions, pharmacies, and distributors, as well as direct sales to consumers [2] Group 2: Acquisition of Huadong Pharmaceutical - The acquisition of Huadong Pharmaceutical has been completed, making it a wholly-owned subsidiary of the company [2] - Huadong Pharmaceutical has a strong presence in the grassroots public medical market and its retail segment ranks among the top in the pharmaceutical retail industry, which aligns well with the company's existing operations [2] - This acquisition is expected to enhance the company's market share in Zhejiang, improve negotiation power with suppliers, and increase influence over end consumers, contributing to high-quality development [2] Group 3: Accounts Receivable Management - The company reports a stable accounts receivable collection cycle, with variations across different regions in Zhejiang and among different customer types [2] - A comprehensive credit risk management system has been established to oversee accounts receivable turnover [2] Group 4: Shitang Pharmaceutical Industrial Park - The company’s wholly-owned subsidiary, Zhejiang Yinte Smart Network Technology Co., Ltd., acquired land for the Shitang Pharmaceutical Industrial Park project, covering an area of 79,357 square meters [3] - The project is aimed at enhancing the company's operational capabilities in the pharmaceutical sector [3]

Market Overview - The pharmaceutical commercial sector declined by 0.5% on November 4, with Baiyang Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3960.19, down 0.41%, while the Shenzhen Component Index closed at 13175.22, down 1.71% [1] Stock Performance - Notable gainers included: - HeFu China (603122) with a closing price of 11.85, up 10.03% [1] - Renmin Tongtai (600829) at 9.71, up 8.01% [1] - Jianfa Zhixin (301584) at 35.42, up 5.20% [1] - Baiyang Pharmaceutical (301015) saw a significant decline, closing at 25.62, down 6.09% [2] - Other notable decliners included: - Yifeng Pharmacy (603939) at 23.76, down 3.22% [2] - Saili Medical (603716) at 24.78, down 3.17% [2] Capital Flow - The pharmaceutical commercial sector experienced a net inflow of 32.34 million yuan from institutional investors, while retail investors saw a net outflow of 41.10 million yuan [2] - The capital flow for key stocks showed: - Renmin Tongtai had a net inflow of 63.04 million yuan from institutional investors [3] - Yifeng Pharmacy experienced a net outflow of 32.44 million yuan from retail investors [3]

Core Insights - The article discusses the performance and financial metrics of Yingte Group, a leading pharmaceutical distribution company in Zhejiang Province, China, highlighting its market position and financial health [1][2][3]. Financial Performance - For Q3 2025, Yingte Group reported a revenue of 24.963 billion yuan, ranking 8th among 24 companies in the industry, with the industry leader, Shanghai Pharmaceuticals, achieving 215.072 billion yuan [2]. - The net profit for the same period was 381 million yuan, placing the company 10th in the industry, while Shanghai Pharmaceuticals led with a net profit of 5.986 billion yuan [2]. Financial Ratios - As of Q3 2025, Yingte Group's debt-to-asset ratio was 69.03%, slightly down from 69.36% year-on-year, which is above the industry average of 59.74% [3]. - The gross profit margin for Q3 2025 was 6.72%, a slight increase from 6.67% year-on-year, but still below the industry average of 13.11% [3]. Executive Compensation - The chairman and general manager, Wang Yang, received a salary of 2.0137 million yuan in 2024, an increase of 832,900 yuan from 2023 [4]. Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 1.17% to 20,800, while the average number of shares held per shareholder increased by 1.20% to 15,500 [5].

| 证券代码：000411 | 证券简称：英特集团 | 公告编号：2025-045 | | --- | --- | --- | | 债券代码：127028 | 债券简称：英特转债 | | 浙江英特集团股份有限公司 关于子公司英特药业收购华通医药股权的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 一、交易概述 浙江英特集团股份有限公司（以下简称"公司"）于 2025 年 5 月 27 日召开十届十二次董 事会，审议通过了《关于英特药业参与竞拍浙江华通医药集团有限公司 100%股权的议案》， 同意全资子公司浙江英特药业有限责任公司（以下简称"英特药业"）参与竞拍浙江华通医药 集团有限公司（以下简称"华通医药"）100%股权。本次交易具体内容详见公司于 2025 年 5 月 28 日披露在巨潮资讯网（http://www.cninfo.com.cn）和证券时报上的《关于英特药业参与 竞拍浙江华通医药集团有限公司 100%股权的公告》（公告编号：2025-029）。 名称：浙江华通医药集团有限公司 统一社会信用代码：91330621MA2JR8M82F 类 ...

中国国际金融股份有限公司 关于浙江英特集团股份有限公司 收购报告书 之 2025 年第三季度持续督导意见 财务顾问 签署日期：二〇二五年十月 释 义 除非另有说明，以下简称在本持续督导意见中的含义如下： | 本持续督导意见 | 指 | 《中国国际金融股份有限公司关于浙江英特集团股份有限公 | | | | --- | --- | --- | --- | --- | | | | 司收购报告书之 2025 年第三季度持续督导意见》 | | | | 本持续督导期 | 指 | 自 2025 年 7 1 日至 2025 9 月 30 日 | 月 | 年 | | 《收购报告书》 | 指 | 《浙江英特集团股份有限公司收购报告书》 | | | | 财务顾问、中金公司 | 指 | 中国国际金融股份有限公司 | | | | 上市公司、英特集团 | 指 | 浙江英特集团股份有限公司 | | | | 收购人、浙药集团 | 指 | 浙江省医药健康产业集团有限公司 | | | | 浙江国贸 | 指 | 浙江省国际贸易集团有限公司 | | | | 康恩贝 | 指 | 浙江康恩贝制药股份有限公司 | | | | 收购人一致行动人 | 指 | ...

Core Insights - As of October 20, 2025, the number of shareholders for the company is reported to be 21,182 [2] Company Summary - The company, Yingte Group, provided an update on its shareholder count in response to investor inquiries on October 29 [2]

Group 1 - The core point of the article is that Yingte Group (SZ 000411) announced the results of its 10th Board of Directors meeting held on October 27, 2025, via communication voting, where the Q3 2025 report was reviewed [1] - For the first half of 2025, Yingte Group's revenue composition was as follows: pharmaceutical wholesale accounted for 89.1%, pharmaceutical retail accounted for 10.34%, and other industries accounted for 0.56% [1]

浙江英特集团股份有限公司 十届十六次董事会议决议公告 | 证券代码：000411 | 证券简称：英特集团 | 公告编号：2025-043 | | --- | --- | --- | | 债券代码：127028 | 债券简称：英特转债 | | 相关内容披露在同日的巨潮资讯网（http://www.cninfo.com.cn）和证券时报上。 2025 年第三季度报告中的财务信息已经公司董事会审计委员会审核通过。 特此公告。 浙江英特集团股份有限公司董事会 2025 年 10 月 29 日 1 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 2025 年 10 月 22 日，浙江英特集团股份有限公司以电子邮件、专人送达方式向全体董 事发出了召开十届十六次董事会议的通知，会议于 2025 年 10 月 27 日以通讯表决方式召开。 会议应到董事 11 人，实际出席会议的董事 11 人，缺席会议的董事 0 人。本次会议的召开 符合有关法律、行政法规、部门规章、规范性文件和公司章程的规定。会议采用记名表决 方式对通知中所列事项进行了表决，形成以下决议： 一、审议通过了《2 ...